These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38363353)

  • 1. Understanding the impact of non-alcoholic steatohepatitis with metabolic comorbidities on adults: a real-world qualitative study.
    Shinde S; Taylor N; Chinthammit C; Wilson R; Burgess SM; Poon JL
    Curr Med Res Opin; 2024 Apr; 40(4):665-676. PubMed ID: 38363353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding Patient Preferences and Unmet Needs in Non-alcoholic Steatohepatitis (NASH): Insights from a Qualitative Online Bulletin Board Study.
    Cook NS; Nagar SH; Jain A; Balp MM; Mayländer M; Weiss O; Chatterjee S
    Adv Ther; 2019 Feb; 36(2):478-491. PubMed ID: 30547371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A qualitative patient interview study to understand the experience of patients with nonalcoholic steatohepatitis.
    Swain MG; Pettersson B; Meyers O; Venerus M; Oscarsson J
    Hepatol Commun; 2023 Mar; 7(3):e0036. PubMed ID: 36757391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey.
    Nadolsky K; Cryer DR; Articolo A; Fisher T; Schneider J; Rinella M
    Ann Med; 2023 Dec; 55(1):2211349. PubMed ID: 37171239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
    Shelley K; Articolo A; Luthra R; Charlton M
    BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study.
    Doward LC; Balp MM; Twiss J; Slota C; Cryer D; Brass CA; Anstee QM; Sanyal AJ
    Patient; 2021 Sep; 14(5):533-543. PubMed ID: 33336323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thematic analysis to explore patients' experiences with long COVID-19: a conceptual model of symptoms and impacts on daily lives.
    Rofail D; Somersan-Karakaya S; Choi JY; Przydzial K; Zhao Y; Hussein M; Norton TD; Podolanczuk AJ; Mylonakis E; Geba GP
    BMJ Open; 2024 Jan; 14(1):e076992. PubMed ID: 38233059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced fibrosis associated with non-alcoholic steatohepatitis (NASH) in Spain: results of a Delphi study.
    Aller R; Calleja JL; Crespo J; Romero-Gómez M; Turnes J; Benmarzouk-Hidalgo OJ; Subirán R; Gil A
    Gastroenterol Hepatol; 2024 Apr; 47(4):337-346. PubMed ID: 37343722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the Symptom Burden and Impact of Myasthenia Gravis from the Patient's Perspective: A Qualitative Study.
    Jackson K; Parthan A; Lauher-Charest M; Broderick L; Law N; Barnett C
    Neurol Ther; 2023 Feb; 12(1):107-128. PubMed ID: 36322146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palliative care experiences of adult cancer patients from ethnocultural groups: a qualitative systematic review protocol.
    Busolo D; Woodgate R
    JBI Database System Rev Implement Rep; 2015 Jan; 13(1):99-111. PubMed ID: 26447011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qualitative interviews to improve patient-reported outcome measures in late-onset Pompe disease: the patient perspective.
    Hamed A; An Haack K; Gwaltney C; Baranowski E; Stewart A; Krupnick R; Tyler M; Sparks S; Paty J
    Orphanet J Rare Dis; 2021 Oct; 16(1):428. PubMed ID: 34641935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH).
    Povsic M; Wong OY; Perry R; Bottomley J
    Adv Ther; 2019 Jul; 36(7):1574-1594. PubMed ID: 31065991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis.
    McSweeney L; Breckons M; Fattakhova G; Oluboyede Y; Vale L; Ternent L; Balp MM; Doward L; Brass CA; Beyer F; Sanyal A; Anstee QM
    JHEP Rep; 2020 Jun; 2(3):100099. PubMed ID: 32435754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
    Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
    Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry.
    Younossi ZM; Yilmaz Y; Yu ML; Wai-Sun Wong V; Fernandez MC; Isakov VA; Duseja AK; Mendez-Sanchez N; Eguchi Y; Bugianesi E; Burra P; George J; Fan JG; Papatheodoridis GV; Chan WK; Alswat K; Saeed HS; Singal AK; Romero-Gomez M; Gordon SC; Roberts SK; El Kassas M; Kugelmas M; Ong JP; Alqahtani S; Ziayee M; Lam B; Younossi I; Racila A; Henry L; Stepanova M;
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2296-2306.e6. PubMed ID: 34768009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
    Yamamura S; Nakano D; Hashida R; Tsutsumi T; Kawaguchi T; Okada M; Isoda H; Takahashi H; Matsuse H; Eguchi Y; Sumida Y; Nakajima A; Gerber L; Younossi ZM; Torimura T
    J Gastroenterol Hepatol; 2021 Mar; 36(3):629-636. PubMed ID: 32627871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.
    Quek J; Chan KE; Wong ZY; Tan C; Tan B; Lim WH; Tan DJH; Tang ASP; Tay P; Xiao J; Yong JN; Zeng RW; Chew NWS; Nah B; Kulkarni A; Siddiqui MS; Dan YY; Wong VW; Sanyal AJ; Noureddin M; Muthiah M; Ng CH
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):20-30. PubMed ID: 36400097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions.
    Anstee QM; Hallsworth K; Lynch N; Hauvespre A; Mansour E; Kozma S; Marino JP; Bottomley J; Piercy J; Higgins V
    JHEP Rep; 2022 Jan; 4(1):100411. PubMed ID: 34977520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
    Younossi ZM; Ratziu V; Loomba R; Rinella M; Anstee QM; Goodman Z; Bedossa P; Geier A; Beckebaum S; Newsome PN; Sheridan D; Sheikh MY; Trotter J; Knapple W; Lawitz E; Abdelmalek MF; Kowdley KV; Montano-Loza AJ; Boursier J; Mathurin P; Bugianesi E; Mazzella G; Olveira A; Cortez-Pinto H; Graupera I; Orr D; Gluud LL; Dufour JF; Shapiro D; Campagna J; Zaru L; MacConell L; Shringarpure R; Harrison S; Sanyal AJ;
    Lancet; 2019 Dec; 394(10215):2184-2196. PubMed ID: 31813633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.